Multidimensional proteomics platform

多维蛋白质组学平台

• 批准号: 8132940
• 负责人: Yehia Ibrahim
• 金额: $ 19.84万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8132940
• 关键词: Biological; Biological Assay; Biological Markers; Blood capillaries; Capillary Electrophoresis; Chemicals; Clinical; Data; Data Quality; Detection; Development; Devices; Electrophoresis; Electrospray Ionization; Electrostatics; Ensure; Excision; Financial compensation; Frequencies; Gases; Heating; Human; Ions; Liquid substance; Mass Spectrum Analysis; Measurement; Methodology; Microfluidics; Modeling; Molecular Weight; Motion; Pattern; Peptides; Performance; Phase; Post-Translational Protein Processing; Protein Fragment; Protein Isoforms; Proteins; Proteome; Proteomics; Radio; Resolution; Sampling; Scanning; Source; Staging; Time; base; capillary; design; improved; instrument; ion mobility; ionization; mass spectrometer; model design; nano-electrospray; novel; novel strategies; pressure; protein complex; public health relevance; statistics; voltage

DESCRIPTION (provided by applicant): While the development of new protein biomarkers is an exciting prospect, current proteomic measurement capabilities are lacking in key aspects, such as throughput, detection limits for low-abundance proteins, and data quality (including the confidence of protein identifications and under-sampling), and quantitation accuracy. In the result, the measurement quality is generally insufficient to confidently detect trace proteins in broad biomedical analyses, and the throughput possible does not allow the statistics of analyses needed for most purposes. The result is that measurement quality is generally insufficient to confidently detect trace proteins in broad analyses of biomedical samples, and the throughput possible is insufficient to provide statistically meaningful numbers of analyses for most purposes. In addition, most of the current proteomics platforms are best suited for detection of proteolytic peptides, using the "bottom-up" approach which is inefficient for distinguishing between biologically important protein isoforms and for identifications of post translational modifications of proteins. The overall objective of this project is to develop a platform for candidate protein biomarker discovery and verification analyses for application to human bodily fluids that will greatly improve upon existing methodologies in terms of throughput, sensitivity, robustness, and quantitation. The new platform aims at providing greater proteome coverage and enabling quantitative measurements of intact proteins and higher molecular weight peptides at concentrations that are presently problematic. The platform will encompass fast capillary zone electrophoresis (CZE) separation integrated with a novel microfabricated nano-electrospray ionization (nano-ESI) emitter on a microfluidic chip followed by a lower pressure field asymmetric ion mobility spectrometer (FAIMS) interfaced to a high resolution gas phase ion mobility (IMS) separation stage and a high-resolution time-of-flight mass spectrometer (TOF MS), providing accurate mass measurements. The specific aims of this project are to: (1) design a single-use disposable microfluidic chip which incorporates CZE and nano-ESI source, (2) model and develop a reduced pressure FAIMS device for minimizing chemical background levels in analysis of intact proteins, (3) develop an efficient ion activation approach in conjunction with gas-phase IMS separation, and (4) rigorously evaluate the multidimensional proteomics platform with clinical samples. We anticipate that the proposed proteomics platform will provide the overall high sensitivity and separation power, as well as accurate quantitation, required for more effective and higher throughput measurements to discover assay patterns of proteins, protein fragments, and peptides in biological fluids that identify biological states. PUBLIC HEALTH RELEVANCE (provided by applicant): The specific objective of this project is to develop a high-throughput sensitive multidimensional separation platform for quantitative analysis of intact proteins and higher molecular weight peptides from human bodily fluids. The platform will enable condensed-phase protein separations and ionization using capillary zone electrophoresis and nano-electrospray ionization source on a single-use disposable microfluidic chip followed by efficient gas-phase ion mobility separations and mass spectrometry detection.

描述（由申请人提供）：虽然开发新的蛋白质生物标志物是一个令人兴奋的前景，但目前的蛋白质组学测量能力在关键方面缺乏，例如吞吐量、低丰度蛋白质的检测限、数据质量（包括蛋白质鉴定和欠采样的置信度）和定量准确性。结果，在广泛的生物医学分析中，测量质量通常不足以自信地检测痕量蛋白质，并且可能的吞吐量不允许大多数目的所需的分析统计。结果是，测量质量通常不足以自信地检测生物医学样品的广泛分析中的痕量蛋白质，并且可能的吞吐量不足以为大多数目的提供统计上有意义的分析数量。此外，目前大多数蛋白质组学平台最适合于检测蛋白水解肽，使用“自下而上”的方法，这种方法在区分生物学上重要的蛋白质异构体和鉴定蛋白质的翻译后修饰方面效率低下。该项目的总体目标是开发一个候选蛋白质生物标志物发现和验证分析平台，用于人体体液，这将大大提高现有方法的吞吐量，灵敏度，稳健性和定量。新平台旨在提供更大的蛋白质组覆盖范围，并能够在目前存在问题的浓度下对完整蛋白质和高分子量肽进行定量测量。该平台将包括快速毛细管区带电泳（CZE）分离，集成在微流控芯片上的新型微制造纳米电喷雾电离（nano-ESI）发射器，随后是低压场不对称离子迁移谱仪（FAIMS），与高分辨率气相离子迁移（IMS）分离级和高分辨率飞行时间质谱仪（TOF MS）接口，提供精确的质量测量。该项目的具体目标是：(1)设计一种结合CZE和纳米esi源的一次性微流控芯片；(2)模拟和开发一种减压FAIMS装置，以最大限度地减少完整蛋白质分析中的化学背景水平；(3)开发一种有效的离子激活方法，结合气相IMS分离；(4)用临床样品严格评估多维蛋白质组学平台。我们预计，所提出的蛋白质组学平台将提供整体的高灵敏度和分离能力，以及准确的定量，需要更有效和更高的通量测量，以发现生物液体中的蛋白质、蛋白质片段和肽的分析模式，以识别生物状态。